PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
This conversation was about a user's progress pictures from using minoxidil and microneedling to treat hair loss. Other users suggested finasteride as an additional treatment, while cautioning that the drug could have permanent side effects.
The conversation humorously discusses the side effects of finasteride, particularly sexual dysfunction. Users share mixed experiences, with some reporting issues and others not.
Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.
The conversation discusses hair loss treatments like topical finasteride with minoxidil, oral dutasteride, and essential oils. Oral treatments like dutasteride and finasteride are seen as more effective, though some prefer topicals to avoid side effects.
A user shared progress pictures after 15 months on 0.5 mg finasteride, reporting significant hair regrowth starting around 9 months. They no longer see the need for a hair transplant.
The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.
A 24 year old male struggling with the physical and mental effects of balding, being short, and having a micropenis. Suggested treatments include taking medications such as finasteride and minoxidil, lifting weights, and trying not to compare himself to others.
Topical finasteride may reduce more scalp DHT but is seen as inconsistent and messy compared to oral finasteride. Users report mixed results with both forms, with some preferring oral for its convenience and consistent dosing, while others find topical effective but harder to apply.
Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a groupbuy in June. It is purported to have similar effects on hair growth as Dutasteride.
The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.
The conversation discusses whether dermarolling (microneedling) works with oral minoxidil for hair loss treatment. References to studies on microneedling alone and combined with minoxidil are provided.
A groupbuy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.
A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
Finasteride is increasingly prescribed to young men to prevent hair loss, with many users expressing regret for not starting sooner. The conversation highlights the preference for Finasteride, Dutasteride, and Minoxidil over other treatments.
User took Fin for 3 years, Dut for 7 months, and oral Min for 2 months without side effects. Fin stopped hair loss for 2 years, Dut maintained hair, and oral Min regrew thinning hair.
The conversation discusses the results of a groupbuy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A groupbuy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.
The conversation discusses making a RU58841 solution for hair loss prevention and includes personal experiences with using RU58841 and minoxidil for hair regrowth, with a mention of monitoring health effects.
A 33-year-old is using topical minoxidil, oral finasteride (1mg), a derma pen, and 0.05% tretinoin on the hairline to treat hair loss, showing progress after 2 months. They apply tretinoin in the evening with minoxidil and use a derma pen once a week at 1.5mm.
The groupbuy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
Researching the effectiveness of the hair loss treatment Pyril in comparison to other treatments such as Minoxidil, Finasteride, and RU58841. Replies suggest that users often fail to provide updates on their experience with Pyril.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek groupbuy for research chemical.